XRP Price Today (Dec. 21, 2025): $2 Level in Focus as Spot XRP ETF Inflows Top $1B and XRPL Lending Nears Vote

XRP Price Today (Dec. 21, 2025): $2 Level in Focus as Spot XRP ETF Inflows Top $1B and XRPL Lending Nears Vote

December 21, 2025 — XRP is ending the weekend in a familiar spot: hovering just below the psychological $2.00 mark while traders weigh a rare combination of tailwinds (institutional ETF demand and growing “real-world” utility narratives) against a market still prone to sudden selloffs. As of today, XRP is trading around $1.91 with roughly $2.38B in 24-hour volume, and is down about 1% over the last 24 hours, according to CoinMarketCap’s live market data. CoinMarketCap That headline number, however, masks the more important story driving XRP price discussion on 21.12.2025: spot XRP ETFs are still pulling in steady inflows, yet
21 December 2025
Bitcoin Price Today (Dec. 21, 2025): BTC Holds Near $88K as ETF Flows Whipsaw and 2026 Forecasts Cool

Bitcoin Price Today (Dec. 21, 2025): BTC Holds Near $88K as ETF Flows Whipsaw and 2026 Forecasts Cool

Bitcoin is ending the weekend in “wait-and-see” mode. On Sunday, December 21, 2025, BTC traded around $88,400, after moving between roughly $87,600 and $89,000 intraday—keeping the market pinned just below the psychologically important $90,000 level. Yahoo Finance That range-bound action comes after a bruising fourth quarter: Bitcoin is still about 30% below its early-October record high near $126,223, and the debate across trading desks has shifted from “how fast can BTC make new highs?” to “what finally breaks the stalemate—macro, ETF flows, or an on-chain supply squeeze?” Reuters+2Reuters+2 Below is a full roundup of the most current news, forecasts, and
21 December 2025
Larry Page’s 2000 AI Prediction Is Google’s 2025 Reality as Gemini 3 Rolls Out — and Investors Take Notice

Larry Page’s 2000 AI Prediction Is Google’s 2025 Reality as Gemini 3 Rolls Out — and Investors Take Notice

On December 21, a 25-year-old clip of Google co-founder Larry Page began circulating again for a simple reason: it sounds like a script for today’s AI race. In the footage, recorded in 2000—just two years after Google was founded—Page describes what he called the “ultimate search engine”: one that understands everything on the web, figures out exactly what you want, and gives you the right answer. He immediately labels that end-state for search as artificial intelligence. The Times of India+1 Fast-forward to late 2025, and Google is actively reshaping its most important products around that exact idea—shipping new Gemini 3
Silver Price Today (Dec. 21, 2025): XAG/USD Holds Near $67 After Record Highs—Latest News, Forecasts, and Key Levels to Watch

Silver Price Today (Dec. 21, 2025): XAG/USD Holds Near $67 After Record Highs—Latest News, Forecasts, and Key Levels to Watch

Silver is closing out 2025 with the kind of momentum that forces both bulls and bears to pay attention. As of Sunday, December 21, 2025, the silver price (XAG/USD) is hovering around the $67-per-ounce area after a record-setting surge late last week—powered by a mix of investment flows, tight supply conditions, and an industrial demand narrative that keeps getting louder. Reuters+1 But this is also the point in a parabolic move where markets tend to change character: liquidity thins into the holidays, positioning gets crowded, and even small headlines can trigger outsized swings. Several analysts publishing today warn that a
21 December 2025
Gold Price Today (Dec. 21, 2025): XAU/USD Near $4,350 as Fed “Pause” Talk Meets $5,000 Forecasts for 2026

Gold Price Today (Dec. 21, 2025): XAU/USD Near $4,350 as Fed “Pause” Talk Meets $5,000 Forecasts for 2026

Gold is ending 2025 where it spent much of the year: near record territory, with investors debating whether the next move is a breakout—or a breath. As of Sunday, December 21, 2025, live spot pricing put gold around $4,352/oz, keeping the metal within striking distance of its 2025 record near $4,381/oz and reinforcing the narrative that bullion has shifted from a “rate-cut trade” into a structural portfolio asset for central banks and investors alike. JM Bullion+2Reuters+2 What makes today’s setup especially interesting is the collision of three powerful themes: fresh signals that the Federal Reserve could keep rates steady for
21 December 2025
US Stock Market Outlook (Dec. 21, 2025): S&P 500 Eyes a Santa Rally as Fed Signals, AI Jitters, and GDP Data Shape Year-End Trading

US Stock Market Outlook (Dec. 21, 2025): S&P 500 Eyes a Santa Rally as Fed Signals, AI Jitters, and GDP Data Shape Year-End Trading

NEW YORK — The U.S. stock market heads into the final holiday-shortened stretch of 2025 with investors balancing two competing realities: a strong year for major indexes, and a choppier, more skeptical tone beneath the surface as Wall Street debates the durability of the AI-led boom and the next leg of Federal Reserve policy. On Friday’s close (the last full session before Sunday’s outlook pieces), the S&P 500 finished at 6,834.50, the Nasdaq Composite at 23,307.62, and the Dow Jones Industrial Average at 48,134.89. Stocks ended the day higher—helped by a rebound in technology—while the week overall was mixed: the
21 December 2025
Dow Jones Industrial Average (DJIA) Outlook: Santa Rally Watch, Fed Signals, and Key Levels After 48,134 Close (Dec. 21, 2025)

Dow Jones Industrial Average (DJIA) Outlook: Santa Rally Watch, Fed Signals, and Key Levels After 48,134 Close (Dec. 21, 2025)

The Dow Jones Industrial Average (DJIA) is heading into the Christmas trading week with a familiar end‑of‑year mix: upbeat annual performance, a choppy December tape, and a market narrative that keeps pivoting between “Santa rally” optimism and late‑cycle caution. The Dow last closed at 48,134.89 on Friday, finishing the day higher but ending the week modestly lower as investors weighed fresh inflation data, AI‑linked volatility, and a Federal Reserve outlook that’s becoming more contested inside the central bank itself. Reuters+1 Dow Jones today: strong year, uneven December In 2025, the big picture still looks constructive. The blue‑chip Dow is up
Accenture Earnings Beat as Advanced AI Bookings Hit $2.2 Billion—But 2026 Outlook Keeps Wall Street Cautious

Accenture Earnings Beat as Advanced AI Bookings Hit $2.2 Billion—But 2026 Outlook Keeps Wall Street Cautious

Accenture’s latest earnings update is a snapshot of where enterprise AI is right now: real budgets, real contracts, and increasingly “baked in” to broader transformation work—yet still paired with investor anxiety about what AI could automate and where spending is tightening. As of December 21, 2025, the consulting and IT services giant is coming off a quarter where it beat revenue expectations, posted strong new bookings, and highlighted a surge in advanced AI demand—while also acknowledging uneven public-sector momentum and offering a second-quarter revenue outlook that landed a touch below what analysts were modeling. Reuters+2Accenture Newsroom+2 The headline numbers: revenue,
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

As the market heads into a Christmas-shortened trading week, Johnson & Johnson (NYSE: JNJ) is entering the final stretch of 2025 with an unusually headline-heavy mix of catalysts: U.S. drug-pricing negotiations tied to the White House, new talc-related jury verdicts, and a string of FDA and clinical updates that reinforce the company’s longer-term growth narrative. As of the latest close (Friday, December 19, 2025), JNJ ended around $206/share, keeping the stock in a tight, late-year range while investors weigh whether policy risk and litigation uncertainty outweigh the steadier benefits of new product momentum and “defensive” healthcare positioning. MarketBeat Below is
Exxon Mobil Stock (XOM) Week Ahead Outlook: Oil Prices, Analyst Targets, and Key Catalysts for Dec 22–26, 2025

Exxon Mobil Stock (XOM) Week Ahead Outlook: Oil Prices, Analyst Targets, and Key Catalysts for Dec 22–26, 2025

As of Sunday, December 21, 2025, Exxon Mobil Corporation (NYSE: XOM) is heading into a holiday-shortened trading week with two big forces likely to drive near-term price action: oil-market volatility and fresh investor digestion of Exxon’s upgraded 2030 plan. XOM was last quoted around $116.69. This week’s market structure matters: the NYSE will close early at 1:00 p.m. ET on Wednesday, Dec. 24, and the market will be closed on Thursday, Dec. 25 (Christmas Day). New York Stock Exchange+1 And despite a U.S. federal government closure directive for Dec. 24 and Dec. 26, major U.S. exchanges said they will remain
Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce, Inc. (NYSE: CRM) heads into the Christmas holiday week with a busy backdrop for investors: fresh product distribution news for its Agentforce platform, a newly announced acquisition aimed at “agentic” marketing, and a market calendar that’s likely to amplify day-to-day volatility simply because liquidity is thinner than usual. As of Sunday, December 21, 2025, the latest available trade data puts Salesforce stock around $259.91, following Friday’s (Dec. 19) close. StockAnalysis For the coming week, CRM stock is less about an earnings catalyst (Salesforce just reported) and more about how investors handicap AI monetization, M&A integration, and macro-driven risk appetite
AppLovin (APP) Stock Week Ahead: Fresh Analyst Targets, Axon AI Momentum, and Key Risks to Watch (Dec. 22–26, 2025)

AppLovin (APP) Stock Week Ahead: Fresh Analyst Targets, Axon AI Momentum, and Key Risks to Watch (Dec. 22–26, 2025)

Date: December 21, 2025 (Sunday) — outlook for the coming trading week AppLovin Corporation (NASDAQ: APP) heads into the Christmas-shortened week with investor attention still locked on the same powerful mix that defined much of 2025: rapid growth, unusually high profitability, and a bullish Wall Street narrative around its AI-driven ad engine (Axon). But with APP trading near prior highs after a huge run, the week ahead is less about scheduled company events and more about liquidity, macro headlines, analyst note flow, and any surprise developments tied to regulation or litigation. Below is a detailed, publication-ready, week-ahead report based on
21 December 2025
Walmart Stock (WMT) Week Ahead: What to Watch After the Nasdaq Switch, CEO Transition, and Holiday-Shortened Trading Week

Walmart Stock (WMT) Week Ahead: What to Watch After the Nasdaq Switch, CEO Transition, and Holiday-Shortened Trading Week

Dec. 21, 2025 — Walmart Inc. (ticker: WMT) heads into the Christmas week trading window with investors balancing upbeat operational momentum against a burst of headline risk from Washington, regulators, and the courts. The stock last traded around $114.36 after Friday’s close, setting the stage for a holiday-shortened week that can amplify moves—up or down—because liquidity and volume are typically thinner. StockAnalysis This week’s backdrop is unusual even by late-December standards: U.S. markets close early on Wednesday (Dec. 24) and are shut on Thursday (Dec. 25), compressing price discovery into fewer hours. Investopedia+2NYSE+2 Meanwhile, Walmart shareholders are digesting a leadership
21 December 2025
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in a single session. Investing.com+2Reuters+2 As of Sunday, December 21, 2025, the weekend narrative around BioMarin stock is dominated by that deal—and what it signals: a sharper pivot toward durable rare-disease commercial franchises, an attempt to reduce dependence on BioMarin’s fast-growing
CoreWeave (CRWV) Stock Week Ahead Forecast: DOE Genesis Mission Boost, Citi “Buy/High Risk,” and Holiday-Week Catalysts (Dec. 22–26, 2025)

CoreWeave (CRWV) Stock Week Ahead Forecast: DOE Genesis Mission Boost, Citi “Buy/High Risk,” and Holiday-Week Catalysts (Dec. 22–26, 2025)

Date: Dec. 21, 2025 (Sunday) — U.S. markets reopen Monday after a volatile week for CoreWeave, Inc. (Nasdaq: CRWV). CoreWeave stock is heading into the Christmas-shortened trading week with momentum—and a spotlight that’s only getting brighter. After a sharp selloff that fueled “AI bubble” chatter across Wall Street, CRWV ripped higher on Friday, Dec. 19, closing at $83.00, up $15.32 (+22.64%) in a single session. MarketBeat What triggered the rebound? Two headlines investors are likely to keep trading in the week ahead: Below is a detailed, week-ahead report on the news, forecasts, and key catalysts shaping CoreWeave stock as of
21 December 2025
Intel Stock (INTC) Week Ahead: Nvidia Deal Clearance, US Government Backing, and Holiday-Shortened Trading Risks (Dec. 22–26, 2025)

Intel Stock (INTC) Week Ahead: Nvidia Deal Clearance, US Government Backing, and Holiday-Shortened Trading Risks (Dec. 22–26, 2025)

Intel Corporation stock (NASDAQ: INTC) heads into the week of December 22–26, 2025 with a rare mix of catalysts that are both market-moving and hard to handicap: a newly cleared Nvidia investment, deepening U.S. government involvement, and a Christmas-shortened trading week that can amplify volatility on lighter volume. As of the latest close (Friday, Dec. 19, 2025), Intel shares were around $36.82. MarketBeat Below is what matters most for Intel stock this week, what Wall Street is projecting, and the specific events that could swing sentiment—especially in thin holiday liquidity. Intel stock snapshot heading into Dec. 22 Intel enters the
21 December 2025
Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

As of Sunday, December 21, 2025, Eli Lilly and Company (NYSE: LLY) heads into a holiday-shortened trading week near recent highs, after a busy stretch of headlines spanning next-generation obesity drugs, potentially accelerated FDA review timelines, price cuts aimed at widening access, and a fast-evolving U.S. drug-pricing agenda. The stock’s setup for the week ahead is straightforward: fundamentals and pipeline momentum remain the core bull case, while the key overhangs are pricing pressure, policy uncertainty, and headline-driven volatility typical of a late-December tape. Eli Lilly stock price check: where LLY stands heading into the week LLY last traded around $1,071
CoreWeave Stock (NASDAQ: CRWV): Latest News, Analyst Forecasts, and 2026 Outlook as of December 21, 2025

CoreWeave Stock (NASDAQ: CRWV): Latest News, Analyst Forecasts, and 2026 Outlook as of December 21, 2025

CoreWeave, Inc. (NASDAQ: CRWV) has become one of the most watched—and most debated—AI infrastructure stocks of 2025. As of December 21, 2025 (a Sunday, with U.S. markets closed), CoreWeave shares are sitting near $83, after a sharp late-week rebound that followed weeks of volatility and “AI bubble” hand-wringing across Wall Street. The timing matters: the stock’s latest surge didn’t come from a single earnings print. Instead, it arrived at the intersection of (1) new/renewed bullish coverage from Wall Street, (2) fresh credibility signals from government and NVIDIA, and (3) investor anxiety about leverage, customer concentration, and data-center execution risk—the “boring”
21 December 2025
Ondas Holdings (ONDS) Stock News on Dec. 21, 2025: December Deals, Defense Expansion, and Analyst Forecasts for 2026

Ondas Holdings (ONDS) Stock News on Dec. 21, 2025: December Deals, Defense Expansion, and Analyst Forecasts for 2026

Dec. 21, 2025 — Ondas Holdings Inc. (NASDAQ: ONDS) has become one of the market’s more polarizing small-cap defense-tech stories: part autonomous drones, part counter-drone (“counter-UAS”), part ground robotics, and—often forgotten in the headlines—part private industrial wireless networking. December brought a rapid sequence of acquisitions, contract wins, and SEC filings that collectively reshaped the near-term narrative for Ondas Holdings stock heading into 2026. Ondas Holdings Inc.+2Ondas Holdings Inc.+2 As of the most recent close (Friday, Dec. 19, 2025), ONDS finished around $9.22, up roughly 18% on the day, after an unusually heavy session with roughly 125.8 million shares traded—eye-catching volume
Nike Stock (NKE) Week-Ahead Outlook: Tariffs, China, and Post-Earnings Volatility in Focus (Dec. 22–26, 2025)

Nike Stock (NKE) Week-Ahead Outlook: Tariffs, China, and Post-Earnings Volatility in Focus (Dec. 22–26, 2025)

As of Dec. 21, 2025, Nike, Inc. (NYSE: NKE) enters a holiday-shortened week with investors still digesting a sharp post-earnings selloff—and with a familiar question back at center stage: is the turnaround gaining traction, or simply getting more expensive? Reuters Nike shares closed at $58.71 on Friday (Dec. 19) after dropping roughly 11%, marking a seven-month low and leaving the stock down about 22% year-to-date (per Reuters). Reuters For the coming week (Dec. 22–26), trading conditions will matter as much as headlines. The NYSE will close early at 1:00 p.m. ET on Wednesday, Dec. 24, and will be closed on

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop